Reuters logo
14 天前
BRIEF-Heron Therapeutics initiates phase 3 program for HTX-011
2017年8月9日 / 晚上8点28分 / 14 天前

BRIEF-Heron Therapeutics initiates phase 3 program for HTX-011

Aug 9 (Reuters) - Heron Therapeutics Inc

* Heron Therapeutics announces initiation of phase 3 program for HTX-011 in postoperative pain following successful end-of-phase 2 meeting with FDA

* ‍Phase 3 program expected to enable broad indication​

* ‍NDA filing planned for 2018​

* ‍FDA noted beyond agreed-upon phase 3 studies,no additional clinical work needed to meet "combination rule" for fixed-dose combination products​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below